52610-77-2

Basic information

• Product Name: SOLANESYL BROMIDE
• Synonyms: SOLANESYL BROMIDE;(2E,6E,10E,14E,18E,22E,26E,30E)-1-BroMo-3,7,11,15,19,23,27,31,35-nonaMethyl-;2,6,10,14,18,22,26,30,34-hexatriacontanonaene;trans-Solanesyl BroMide
• CAS NO: 52610-77-2
• Molecular Formula: C₄₅H₇₃Br
• Molecular Weight: 693.97
• Product Categories: Nicotine Derivatives
• Mol File: 52610-77-2.mol

Chemical Properties

• Boiling Point: 692.3°C at 760 mmHg
• Flash Point: 370.2°C
• Appearance: /
• Density: 0.956g/cm³
• Vapor Pressure: 3.16E-18mmHg at 25°C
• Refractive Index: 1.511
• Storage Temp.: -20°C Freezer
• Solubility: Benzene (Slightly), Chloroform (Slightly)
• Stability: Light Sensitive
• CAS DataBase Reference: SOLANESYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: SOLANESYL BROMIDE(52610-77-2)
• EPA Substance Registry System: SOLANESYL BROMIDE(52610-77-2)

Safety Data

• Hazardous Substances Data: 52610-77-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
SOLANESYL BROMIDE is used as a pharmaceutical agent for its potential therapeutic applications. It has been found to have anti-inflammatory, anti-cancer, and immunosuppressive properties, making it a promising candidate for the development of new drugs.
Used in Cosmetic Industry:
SOLANESYL BROMIDE is used as an ingredient in cosmetic products for its potential skin care benefits. It has been reported to have anti-aging, moisturizing, and skin brightening effects, making it a valuable component in skincare formulations.
Used in Food Industry:
SOLANESYL BROMIDE is used as a natural additive in the food industry for its potential health benefits. It has been found to have antioxidant and anti-inflammatory properties, which can contribute to the overall health and well-being of consumers.

InChI:InChI=1/C45H73Br/c1-37(2)19-11-20-38(3)21-12-22-39(4)23-13-24-40(5)25-14-26-41(6)27-15-28-42(7)29-16-30-43(8)31-17-32-44(9)33-18-34-45(10)35-36-46/h19,21,23,25,27,29,31,33,35H,11-18,20,22,24,26,28,30,32,34,36H2,1-10H3/b38-21+,39-23+,40-25+,41-27+,42-29+,43-31+,44-33+,45-35+

Upstream product

• 28072-21-1 isosolanesol 
• 13190-97-1 solanesol 

Downstream Products

• 103190-36-9 N,N'-bis(3,4-dimethoxybenzyl)-N-solanesylethylenediamine 
• 303-97-9 ubiquinone-45 
• 5677-54-3 ubiquinone-9 
• 83626-22-6 2,3-Dimethoxy-6-methyl-4-((2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethyl-hexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyloxy)-phenol 
• 83626-18-0 Acetic acid 4-hydroxy-2,3,6-trimethyl-5-((2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethyl-hexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl)-phenyl ester 
• 294674-88-7 solanesyl sulphone 
• 523-39-7 2-methyl-3-((2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35- nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-yl)naphthalene-1,4-dione 
• 74813-93-7 4-(benzenesulfonyl)-3,7,11,15,19,23,27,31,35,39-decamethyl-1-[3,4-dimethoxy-2,5-bis(methoxymethoxy)-6-methylphenyl]tetraconta-2,6,10,14,18,22,26,30,34,38-decaene 
• 899809-09-7 C₇₃H₁₀₄O₆S 
• 70854-63-6 1,4-bis(benzyloxy)-2-{(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-5-[(4-methylphenyl)sulfonyl]tetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl}-5,6-dimethoxy-3-methylbenzene 
• 94828-16-7 1-(5'-p-tosyl-all-trans-decaprenyl)-2-methyl-3,4,5,6-tetramethoxybenzene 
• 94828-18-9 1-((2E,5E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-tetraconta-2,5,10,14,18,22,26,30,34,38-decaenyl)-2,3,4,5-tetramethoxy-6-methyl-benzene 
• 94827-96-0 2-((2E,5E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-tetraconta-2,5,10,14,18,22,26,30,34,38-decaenyl)-5,6-dimethoxy-3-methyl-[1,4]benzoquinone 
• 83110-38-7 1-((2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl)-3,4-dimethoxy-2,5-bis((2-methoxyethoxy)methoxy)-6-methylbenzene 

Relevant articles and documents

Solanesol derived therapeutic carriers for anticancer drug delivery

Metabolites of a large number of inert drug carriers can cause long-term exogenous biological toxicity. Therefore, carriers with simultaneous therapeutic effects may be a good choice for drug delivery. Herein, a series of pharmacologically active solaneso

Synthesis of solanesyl phosphonate

Three solanesyl phosphonates were synthesized using standard Arbuzov reaction, and their structures were determined by ESI-MS, NMR, and IR. Copyright Taylor & Francis Group, LLC.

Synthesis of [3′-14C] coenzyme Q10

Radio-labelled coenzyme Q10, labelled at the 3′-position with 14C, was synthesized starting from natural solanesol and ethyl [3-14C] acetoacetate. The radiochemical yield was 8.0% from ethyl [3-14C] acetoacetate

A solanesol-derived scaffold for multimerization of bioactive peptides

A flexible molecular scaffold bearing varying numbers of terminal alkyne groups was synthesized in five steps from solanesol. R(CO)-MSH(4)-NH2 ligands, which have a relatively low affinity for binding at the human melanocortin 4 receptor (hMC4R), were prepared by solid phase synthesis and were N-terminally acylated with 6-azidohexanoic acid. Multiple copies of the azide N3(CH2)5(CO)-MSH(4)-NH2 were attached to the alkyne-bearing, solanesol-derived molecular scaffold via the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. Control studies showed that the binding affinity of the triazole-containing ligand, CH 3(CH2)3(C2N3)(CH 2)5(CO)-MSH(4)-NH2, was not significantly diminished relative to the corresponding parental ligand, CH3(CO)- MSH(4)-NH2. In a competitive binding assay with a Eu-labeled probe based on the superpotent ligand NDP-α-MSH, the monovalent and multivalent constructs appear to bind to hMC4R as monovalent species. In a similar assay with a Eu-labeled probe based on MSH(4), modest increases in binding potency with increased MSH(4) content per scaffold were observed.

Synergistic factors ensue high expediency in the synthesis of menaquinone [K2] analogue MK-6: Application to access an efficient one-pot protocol to MK-9

Here we report a practical and efficient method for the synthesis of menaquinone vitamin (K2) analog MK-6 in all trans forms through “1 + 5 convergent synthetic approach” of pentaprenyl chloride with monoprenyl menadione derivative. In the synergistic factors, less efficient leaving group/more efficient nucleophile (Cl) in the substrate makes it more prominent reaction by eliminating all Sn2’ side reaction products. Further, the addition of acetic acid in the last step (desulfonation) of reaction sequence removes the limitations of the reactions in terms of cyclized side product (multiple reactions of pentaprenyl alcohol with Et3B), byproduct (Et3B, incendiary compound) formations and their interruption in the tricky purification processes. The utility of this method was further extended to find an efficient one-pot synthesis to MK-9 to the gram scale synthesis. This approach is economical and efficient and avoids the awkward chromatographic separation processes.

New efficient synthesis of ubiquinones

A strategy for the ecofriendly and high-yielding synthesis of ubiquinones starting from simple materials and using mild conditions is reported. CoQ1, CoQ2, CoQ3, and CoQ9 were prepared. Copyright Taylor & Francis Group, LLC.

Novel Intermediates, Process for Their Preparation and Process for the Preparation of Coq10 Employing the Said Novel Intermediates

The present invention relates to an improved process for the preparation of Coenzyme Q. Coenzyme Q10 or CoQ10 has the chemical name 2-[(all-trans)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl-1,4-benzoquinone and has the formula I. The invention also provides new intermediates useful for the preparation of CoQ10 and processes for their preparation.

IMPROVED PROCESSES FOR THE PREPARATION OF PURIFIED SOLANESOL, SOLANESYL BROMIDE AND SOLANESYL ACETONE

The present invention relates to processes for the prepartion of purified solanesol, solanesyl bromide and solanesyl acetone. Solanesyl acetone has the chemical name - all - trans 6, 10, 14, 18, 22, 26, 30, 34, 38 -nonamethyl -5,9, 13, 17, 21, 25, 29, 33, 37- triacontanonaen-2-one, of formula (I) and is used for synthesis of coenzyne Q10.

Synthetic studies on coenzyme Q10: Part 31) - An improved C5 + C45 approach to the stereoselective synthesis of coenzyme Q10 via metal-halogen exchange strategy

An efficient and stereoselective approach to the synthesis of coenzyme Q10 is described (Scheme). The MeOCH2-protected p-hydroquinone 4 containing the C5 (E)-allyl (tert-butyl) dimethylsilyl ether moiety was obtained via a halogen-lithium exchange of the MeOCH2-proctected 2-bromo-5,6-dimethoxy-3-methylhydroquinone 2 and subsequent addition to (E)-(tBuMe2Si)-OCH 2C(Me)= CHCH2Br (3). The reductive desulfonylation of compound 8, obtained from 4 via 5-7, was successfully carried out by employing Li/EtNH2.

Radical-scavenging polyphenols: New strategies for their synthesis

New strategies for the synthesis of polyphenols, compounds with antioxidant properties contained in every kind of plants, are discussed. Syntheses of different classes of polyphenols, namely ubiquinones, present in many natural systems in which electron-transfer mechanisms are involved, hydroxytyrosol, one of the main components of the phenol fraction in olives, and flavonoids, widespread in the plant kingdom, were approached by simple and environmentally sustainable methods.